Quick Take #3: Sept 25 Updates! Part 1: Old Drugs For New Indications (Ketamine, Strattera, Flexeril) And Some Antidepressants On The Horizon (Nelivaptan and Seltorexant)

episode

Previously titled “Quick Take #3: September Updates! Part 1: Old Drugs For New Indications (Ketamine, Strattera, Flexeril) And Some Antidepressants On The Horizon (Nelivaptan and Seltorexant)” — renamed by the publisher on Aug 2, 2026

This Is Your Brain On Drugs Psychiatry Podcast not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

recent transcribed audio

The Ezra Klein Show: Jensen Huang Thinks A.I. Alarmism Has Gone Too Far 1h 50m · 25 Sep 2026 · Hard Fork

Pretty Little Episode #110 26 min · 25 Sep 2026 · Handsome

Be Upfront About How You Make Money From Your Podcast 2 min · 25 Sep 2026 · One Minute Podcast Tips - Be a Better Podcaster in Just 60 Seconds

High Stakes US-China Sit Down & Flock Surveillance Under Scrutiny | 9.25.26 19 min · 25 Sep 2026 · Morning Wire

Trump Spooked by Plane at Xi Meeting & Sen. Tuberville Rails Against Flying Furries | Merritt Wever 37 min · 25 Sep 2026 · The Daily Show: Ears Edition

Ireland collapse in Kosovo as Israel game looms 13 min · 25 Sep 2026 · Today with David McCullagh

Report any issue

Source

Recorded13 Sep 2025

Publisherfeeds.podcastle.ai

Handlerec:12104219

Show notes

Welcome back to my second episode covering several snippets of breaking news on psychiatric medications. In these episodes I don't deep dive like normal, but instead cover several important breaking news items that affect psychopharmacology and give my quick take on the news. Some of this will be trial results, FDA updates, interesting papers that were recently published, and anything else I can come up with. I have a ton of updates since the last episode. So much that I had to break it up into two episodes. The next one will be out next week. Today I'm going to talk about new approvals of old medications from new ketamines, KETARx and Nrx100, to Tonmya(r) (cyclobenzaprine) for fibromyalgia. Then, I'll also talk about some combination products containing atomoxetine (Strattera(r)) for obstructive sleep apnea. Lastly, I'll then go into a couple medications with new Phase II trial data for depression. First is a unique vasopressin 1b antagonist and the second is a selective orexin receptor antagonist. I do a bit more discussion on these topics than in the previous update episode because honestly I'm not happy about a lot of this and I want to use these new approvals to talk about the deeper issue of how these drug companies manipulate to make money. Please have a listen!

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related